Skip to content. | Skip to navigation

Garvan Institute

Sections
 

Colon and Lung Cancer

 

Group Leader
Associate Professor Maija Kohonen-Corish

 

Colon and lung cancers are among the most common malignancies. We are identifying new epigenetic biomarkers of prognosis and therapeutic responsiveness, in order to improve the clinical management of cancer. This work involves three main approaches (1) study of cancer specimens from patients (2) analysis of cancer cells grown in cell culture and (3) study of tumours in the mouse.

Our research in colon cancer is focused on understanding how and why cancer develops and how it should be best treated. We have made the unexpected discovery that an arthritis drug sulindac used in humans can actually cause cancer in the mouse. Paradoxically, sulindac – as well as other NSAIDs – is known for its anti-inflammatory and anti-cancer properties. NSAIDs can be prescribed to individuals who have inherited high-risk cancer susceptibility genes, to prevent colon tumours. However, we have shown that sulindac has opposite effects in different parts of the mouse colon – it prevents cancer in the distal colon but is carcinogenic in the proximal colon. Interestingly some mouse strains are particularly susceptible to develop this severe side effect of sulindac, and we are now investigating which genes are responsible for the increased susceptibility.

Another major area of recent work involves the rediscovery of ‘Mutated in Colorectal Cancer’ (MCC) as a candidate tumour suppressor gene. MCC is emerging as a multifunctional protein that regulates several cellular processes and pathways. We have shown that MCC expression is silenced in up to 50% of colon cancers and have identified new biological functions for this protein, including a role in the DNA damage response and lamellipodia formation. We are now pursuing these functions further in laboratory experiments and our newly engineered MCC knockout mouse.

 

Staff

l_pangon90.jpgSenior Research Officer
Dr Laurent Pangon
Nicola CurreyResearch Assistant
Nicola Currey
Dessislava MladenovaResearch Officer
Dr Dessislava Mladenova
read Dessi's "this week in the lab"
Christa Van KralingenResearch Assistant
Christa Van Kralingen
Visiting/Honorary Researchers
Sam Al-Sohaily
Janindra Warusavitarne
Tina Selinger
Wendy Cooper
Po Yee Yip
Lauren WatkinsResearch Assistant
Lauren Watkins

 

News

 

Improved rationale for attacking colorectal cancer

MEDIA RELEASE: 17 Jan 2011
Some people respond very well to chemotherapy or radiotherapy for colorectal cancer, while others hardly respond at all – a fact that has been a bit of a mystery until now. A team of Garvan scientists believes the outcome may depend on a gene called ‘MCC’ – which happens to be expressed at low levels in a subset of colorectal cancers. Their findings give them a rationale for checking patients' responses to therapy.
 
 

Nuns on the Run from Dubbo to Darlinghurst for Cancer

MEDIA RELEASE: 19 Apr 2009
Led by two Sisters of Charity, The Nuns’ Run will cover the 400 km distance from Dubbo to Darlinghurst in an effort to raise cancer awareness and crucial funds for the establishment of a new $100 million Cancer Centre within the St Vincent’s Research Precinct, Sydney. Embarking on their journey on 24 May, Sisters Helen Clarke and Leone Wittmack are hoping to arrive in Sydney on 5 June.
 
 

Garvan and St Vincent’s to Build $100 million Australian Cancer Centre

MEDIA RELEASE: 22 Oct 2008
The Garvan Institute of Medical Research and St Vincents & Mater Health Sydney will today announce plans to jointly establish a new $100 million Cancer Centre within the St Vincent’s Research Precinct. The Garvan St Vincent’s Campus Cancer Centre (GSVCCC) will integrate internationally acclaimed cancer research with best practice cancer services, enabling research findings to move quickly into patient care.
 
 

Personal tools